Report
Chris Kallos, CFA
EUR 101.80 For Business Accounts Only

Corporate Action: We Recommend Taking up Entitlements. Very High Uncertainty Maintained.

No-moat-rated Mesoblast is raising approximately AUD 12.7 million via an underwritten pro rata entitlement offer to retail investors at AUD 1.40 per share. Proceeds will be combined with approximately AUD 38 million raised under the institutional entitlement offer component and used to fund the company’s Phase 3 clinical programs, commercial manufacturing, and ongoing operations. Under the accelerated nonrenounceable retail entitlement offer, new fully paid shares in Mesoblast will be issued on ...
Underlying
Mesoblast Ltd.

Mesoblast is engaged in the development of regenerative medicine products. Co. has leveraged its proprietary technology platform, based on specialized cells known as mesenchymal lineage adult stem cells ("MLCs"), to establish a portfolio of late-stage product candidates. Co.'s allogeneic, "off the shelf" product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology and hematologic conditions. Each MLC-derived product candidate has technical characteristics, target indications, reimbursement strategy, commercialization potential, and partnering opportunities.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Chris Kallos, CFA

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch